↓ Skip to main content

Dove Medical Press

Polypharmacy or medication washout: an old tool revisited

Overview of attention for article published in Neuropsychiatric Disease and Treatment, October 2011
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
3 news outlets
blogs
1 blog
twitter
18 X users

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
93 Mendeley
citeulike
2 CiteULike
Title
Polypharmacy or medication washout: an old tool revisited
Published in
Neuropsychiatric Disease and Treatment, October 2011
DOI 10.2147/ndt.s24375
Pubmed ID
Authors

Daniel A Hoffman, Mark Schiller, James M Greenblatt, Dan V Iosifescu

Abstract

There has been a rapid increase in the use of polypharmacy in psychiatry possibly due to the introduction of newer drugs, greater availability of these newer drugs, excessive confidence in clinical trial results, widespread prescribing of psychotropic medications by primary care, and pressure to augment with additional medications for unresolved side effects or greater efficacy. Even the new generation of medications may not hold significant advantages over older drugs. In fact, there may be additional safety risks with polypharmacy being so widespread. Washout, as a clinical tool, is rarely done in medication management today. Studies have shown that augmenting therapy with additional medications resulted in 9.1%-34.1% dropouts due to intolerance of the augmentation, whereas studies of medication washout demonstrated only 5.9%-7.8% intolerance to the washout procedure. These perils justify reconsideration of medication washout before deciding on augmentation. There are unwarranted fears and resistance in the medical community toward medication washout, especially at the moment a physician is trying to decide whether to washout or add more medications to the treatment regimen. However, medication washout provides unique benefits to the physician: it establishes a new baseline of the disorder, helps identify medication efficacy from their adverse effects, and provides clarity of diagnosis and potential reduction of drug treatments, drug interactions, and costs. It may also reduce overall adverse events, not to mention a potential to reduce liability. After washout, physicians may be able to select the appropriate polypharmacy more effectively and safely, if necessary. Washout, while not for every patient, may be an effective tool for physicians who need to decide on whether to add potentially risky polypharmacy for a given patient. The risks of washout may, in some cases, be lower and the benefits may be clearly helpful for diagnosis, understanding medication effects, the doctor/patient relationship, and safer use of polypharmacy if indicated.

X Demographics

X Demographics

The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 93 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 15%
Student > Ph. D. Student 12 13%
Other 11 12%
Student > Doctoral Student 11 12%
Student > Bachelor 8 9%
Other 22 24%
Unknown 15 16%
Readers by discipline Count As %
Medicine and Dentistry 32 34%
Psychology 15 16%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Agricultural and Biological Sciences 5 5%
Nursing and Health Professions 4 4%
Other 12 13%
Unknown 20 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 44. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 October 2021.
All research outputs
#932,528
of 25,373,627 outputs
Outputs from Neuropsychiatric Disease and Treatment
#122
of 3,132 outputs
Outputs of similar age
#3,824
of 143,951 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#1
of 12 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 143,951 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.